From Barchart: 2025-02-13 17:24:54

Nu Skin (NYSE:NUS) reported Q4 CY2024 results exceeding revenue expectations but saw an 8.8% sales decline to $445.6 million. Next quarter’s revenue guidance of $355 million fell short of estimates by 12.3%. Non-GAAP profit per share was $0.38, surpassing analyst estimates by 72.3%. Nu Skin engages in direct selling of personal care and dietary supplements. The company faces declining sales, with a 14.9% drop projected for the next quarter and a 2% decline expected over the next 12 months. Despite short-term success, sustained growth is crucial for business quality. Free cash flow margin has been subpar at 3.6%.



Read more at Barchart: Nu Skin (NYSE:NUS) Surprises With Q4 Sales, Stock Jumps 22.3%